4D-Nucleofector细胞核转染系统采用模块化设计，可根据研究者的需求，自行组合数个模块形成一套完整系统。
常用模块组合参考：
常规小规模转染：C+X
贴壁细胞原位转染：C+Y
悬浮+贴壁细胞转染：C+X+Y
大规模转染：C+X+LV
摸索复杂转染条件：C+X+96孔

各模块功能和应用：
1、C模块：4D-Nucleofector系统的控制单元，内置转染程序，将不同的功能单元（模块）整合为一个系统，以运行不同的应用程序。

2、X模块：用于悬浮细胞、或贴壁细胞消化后的小规模转染，转染细胞数量2 10^4至2 10^7。可同时转染2个100 L电转杯、1个16孔电转板条（每孔20 L），每个电转杯、每个孔可独立设置程序。另外在使用96孔模块时，也需要X模块。

3、Y模块：用于贴壁细胞不经消化的原位转染，可同时转染1个24孔电转板条（每孔350 L），每个孔可独立设置程序。

4、LV模块：用于同一种悬浮细胞、或同一种贴壁细胞消化后的大规模转染，转染细胞数量1 10^7至1 10^9。可使用1mL手动进样电转盘、或20mL连续进样电转盘。通常使用X模块小试摸条件，再用LV模块线性放大转染规模。

5、96孔模块：用于同时转染96个样品的细胞，转染细胞数量2 10^4至1 10^6。每个孔可独立设置程序。必须与X模块结合使用。


参考文献：
1.Engineering of CRISPR-Cas12b for human genome editing.Strecker J, et al. Nature (2019) 10(1): 212
2.Gene correction for SCID-X1 in long-term hematopoietic stem cells.Pavel-Dinu M, et al. Nat Commun. (2019) 10 (1): 1634
3.Orthotopic replacement of T-cell receptor a- and ?-chains with preservation of near-physiological T-cell function.Schober K, et al. Nat Biomed Eng (2019) 10: 01
4.Ribonucleoprotein Transfection for CRISPR/Cas9-Mediated Gene Knockout in Primary T Cells.Oh SA, et al. Curr Protoc Immunol (2019) 124(1): e69
5.Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency.Nguyen DN, et al. Nat Biotechnol (2019) 1: 1
6.CRISPR-Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV-host factor interactions. Hultquist JF, et al. Nat Protocols (2019) 14(1): 1-27
7.Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.Chen Cheng, et al. J Med Genetics (2019) 56: 10 17
8.Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Shifrut E, et al. Cell (2018) 175(7): 1985-1971
9.Guide Swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells. Ting PY, et al. Nat Methods (2018) 15(11)
10.Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity.Castiglia S,et al.J Transl Med (2018) 16: 237
11.A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Vakulskas CA,et al.Nat Med (2018) 24(8): 1216-1224
12.Reprogramming human T cell function and specificity with non-viral genome targeting.Roth TL,et al.Nature (2018) 559: 405-9
13.Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.Hu B,et al.Hum Gene Ther (2018)
14.Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.Seki A,et al.J Exp Med (2018) 215(3): 985-997
15.Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.Medvec AR,et al.Mol Ther Methods Clin Dev. (2017) 7; 8: 65-74
16.Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.Hudecek M1,et al.Clin Exp Immunol (2017) 52(4): 355(80)
17.CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors.Bak RO,et al.Cell Rep (2017) 20(3): 750-756
18.CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.Zhang Y,et al.Frontiers in Immunology (2017) 1: 1-9
19.CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Rupp LJ1,et al.Scientific Reports (2017) 7 (1): 737
20.A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.Park RJ, et al.Nat Genet (2017) 49(2): 193-203
立即拨打13521452266，免费咨询4D-Nucleofector核转染系统技术问题+获取报价+申请试用
LONZA中国一级代理商，北京泽平